Afterwards, we took advantage of a patient-derived Cancer Stem Cell (CSC) line (L0627) that shows features typical of the classic molecular phenotype such as the overexpression of EGFR gene to validate the results also in a preclinical model closer to clinic. This evidence concerns the gene EGFR and cancer.